Program Guide – ASCO Meeting Program Guide (2024)

Abstracts & Presentations

The data presented here is from a multicenter, randomized, open-label, controlled Phase III clinical study evaluating the feasibility of short-course radiotherapy (shortRT) sequentially combined with camrelizumab and chemotherapy as neoadjuvant therapy (NAT) for locally advanced rectal cancer (LARC)(UNION). Our aim is to explore the value of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) in assessing the comparative efficacy of short-course and long-course chemoradiotherapy (CRT).

Abstract: LBA3606 | Poster Bd #: 269

Abstracts & Presentations

The demand for alternative, non-invasive methods for colorectal cancer (CRC) screening is substantial. Cell-free DNA (cfDNA) whole genome sequencing (WGS) offers a promising avenue, utilizing diverse fragmentomic data. We aimed to develop a new approach: integrating fragment end motif by size (FEMS) with genomic coverage (COV) of cfDNA to enhance CRC screening.

Abstract: 3066 | Poster Bd #: 211

Abstracts & Presentations

AML is a heterogeneous hematological malignancy with poor prognosis. Several treatments are approved for AML, but clinical trials have shown that current stratification approaches to determine patients’ eligibility produce false positives (treated patients that fail to respond) and negatives (patients not treated but could have responded). Venetoclax + azacitidine (VA) treatment is currently reserved for unfit patients, with younger patients stratified based on their FLT3status, and treated with either intensive chemotherapy (IC), or IC plus midostaurin (MIC). Here, we used phosphoproteomics to build a signature and algorithm that accurately predict which of these approved therapies may be more efficacious for a given patient.

Abstract: 6525 | Poster Bd #: 84

Abstracts & Presentations

177Lu-PSMA-617 is approved for the treatment (tx) of mCRPC. Though tx is associated with improved survival, not all pts experience a benefit. Acquired resistance is common and some pts have intrinsic resistance. There is a lack of data on genomic markers that could aid in selecting pts for tx. In this study, we aim to characterize molecular predictors of benefit to 177Lu-PSMA-617.

Abstract: 5050 | Poster Bd #: 456

Abstracts & Presentations

KEYNOTE-782 (NCT03664024) was a single-arm phase 2 study designed to assess possible biomarkers of response (objective response rate [ORR]) to first-line pembrolizumab + chemotherapy (pemetrexed + carboplatin or cisplatin) in patients with previously untreated metastatic nonsquamous NSCLC. Herein, we examined relationships between the T-cell–inflamed gene expression profile (TcellinfGEP) and other tumor microenvironment consensus signatures and efficacy of pembrolizumab + chemotherapy in an exploratory analysis of KEYNOTE-782.

Abstract: 8578 | Poster Bd #: 442

Abstracts & Presentations

Leptomeningeal metastases (LM) present with a high incidence in EGFR-mutated NSCLC following treatment with first- or second-generation EGFR TKIs. Osimertinib has demonstrated significant clinical efficacy in LM at a double dose (160mg), attributed to its superior blood-brain barrier penetration. This study aims to delineate the clinical efficacy, safety, and pharmaco*kinetic profile of 80mg osimertinib for LM patients exhibiting resistance to earlier-generation EGFR TKIs.

Abstract: 8582 | Poster Bd #: 446

Abstracts & Presentations

Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability. TTFields are delivered by a noninvasive portable device that has the European CE Mark and FDA approval for glioblastoma and mesothelioma. Preclinical non-small cell lung cancer (NSCLC) studies demonstrated that TTFields enhance the antitumor immune response, through disruption of mitosis and subsequent induction of immunogenic cell death. The pivotal, phase III LUNAR study (NCT02973789) in metastatic NSCLC progressing on/after platinum-based therapy demonstrated that TTFields with an immune checkpoint inhibitor (ICI) or docetaxel provided a statistically significant and clinically meaningful 3.3-month improvement in median overall survival (OS) vs an ICI or docetaxel alone, with no added systemic toxicities and no clinically significant difference on quality of life between groups. Despite advances in the treatment of NSCLC, survival rates for stage IV disease remain poor and there is a need for effective and tolerable treatments.

Abstract: TPS8665 | Poster Bd #: 520b

Abstracts & Presentations

Complete mesocolic excision (CME) is being increasingly used for the treatment of right-sided colon cancer although there is still no strong evidence that CME provides better long-term oncological outcomes than D2 dissection. The controversy is mainly regarding the survival benefit from extended lymph node dissection emphasized by CME.

Abstract: 3575 | Poster Bd #: 238

Abstracts & Presentations

Mutations in STK11 and KEAP1, present in approximately 20% and 15% of patients (pts) respectively with NSQ mNSCLC, lead to an immunosuppressive tumor microenvironment and are associated with inferior clinical outcomes with anti-PD-(L)1 based chemo-immunotherapy, especially when co-mutated with KRAS. Pts with tumors bearing STK11, KEAP1and/or KRAS mutations may benefit from combinations with CTLA-4 inhibitors, aimed at increasing immune responses. In the phase 3 POSEIDON trial (NCT03164616), first-line (1L) T+D+CT significantly improved overall survival (OS; HR 0.77 [95% CI 0.65–0.92]; P=0.0030) vs CT. These results were maintained after a median follow-up of >5 years. Subgroup analyses showed sustained OS improvement with T+D+CT vs CT in pts with mNSCLC with STK11 (NSQ), KEAP1(all histologies, due to small sample size), and KRAS (NSQ) mutations (HR [95% CI] 0.57 [0.32–1.04), 0.43 [0.16–1.25], and 0.55 [0.36–0.83], respectively). The TRITON study will further investigate the signal of efficacy observed in the POSEIDON subgroup analysis. The study will compare T+D+CT vs P+CT (a standard treatment for NSQ mNSCLC) in pts with STK11 and/or KEAP1 and/or KRASmutations. The results will help to inform clinical practice and to establish a biomarker-driven treatment strategy for these difficult-to-treat pts.

Abstract: TPS8655 | Poster Bd #: 515b

Abstracts & Presentations

Lungs are the most common metastatic area for many cancers. Due to heterogeneous characteristics of primary cancers, the benefit of pulmonary metastasectomy (PM) has not been investigated other than colorectal cancers. Furthermore, well-designed trials in this field are difficult to undertake due to diverse clinical scenarios and therapy related to primary cancers. This study aims to investigate the clinical outcomes of PM for non-primary lung cancer by synthesizing existing literature.

Abstract: 8639 | Poster Bd #: 503

Abstracts & Presentations

Tepotinib, a highly selective MET inhibitor, showed robust and durable activity in patients with METex14 skipping NSCLC in the VISION trial (NCT02864992) (1). Systemic and intracranial activity was seen in patients with brain metastases. Secondary endpoints in the overall population showed stability in overall HRQoL, dyspnea and chest pain, with clinically meaningful improvement in cough. We analyzed HRQoL in patients with brain, liver, adrenal or bone metastases.

Abstract: 8575 | Poster Bd #: 439

Abstracts & Presentations

Cancer-associated cachexia (CAC), a major contributor to mortality in patients with non-small cell lung cancer (NSCLC), is characterized by alterations in body composition. Here, we explore the associations between body composition changes and the pattern of lung cancer metastatic spread.

Abstract: 12095 | Poster Bd #: 224

Abstracts & Presentations

Immune checkpoint inhibitors (ICI) improved outcomes of patients (pts) with advanced melanoma. Nevertheless, a significant number have immune-mediated adverse event (iAE). Due to the impact on quality of life and other therapeutic options, early identification of pts with increased risk of iAE is needed. CD8 immuno-PET with [89Zr] crefmirlimab berdoxam (Zr-Df-IAB22M2C) has shown to be a specific tool to visualize CD8+ T cells mediating both anti-tumor immune response and inflammatory adverse effects rendering this an innovative evaluation method in the field of immuno-oncology.

Abstract: TPS9601 | Poster Bd #: 384a

Abstracts & Presentations

Ensartinib is an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), which has shown systemic and central nervous system efficacy in ALK-positive non-small cell lung cancer (NSCLC) and superiority over crizotinib in the first-line setting. This single-arm phase-1b study evaluates the efficacy of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive advanced NSCLC.

Abstract: 8624 | Poster Bd #: 488

Abstracts & Presentations

CheckMate 67T (NCT04810078), a multicenter, randomized, open-label, phase 3 study, evaluated pharmaco*kinetics and objective response rate (ORR) noninferiority of NIVO SC vs IV in previously treated patients with advanced/metastatic ccRCC. Noninferiority endpoints of exposure (time-averaged serum concentration over the first 28 days and trough serum concentration at steady state) and efficacy (ORR by BICR) were met. Safety was comparable in the SC vs IV arms. NIVO-related immunogenicity was as expected for SC administration and further assessments did not identify apparent clinically meaningful impact. This report focuses on additional safety analyses and PROs.

Abstract: 4532 | Poster Bd #: 227

Abstracts & Presentations

Sotevtamab is an investigational humanized monoclonal antibody that binds to tumor associated secreted clusterin (TA-sCLU). TA-sCLU is a potent inducer of the epithelial-to-mesenchymal transition (EMT), a process known to contribute to tumor invasion, metastasis, chemoresistance and immune evasion. Sotevtamab abrogates the EMT-promoting activity of TA-sCLU by inhibiting its ability to be internalized in cancer cells.

Abstract: 8577 | Poster Bd #: 441

Abstracts & Presentations

The combination of immune checkpoint inhibitors and antiangiogenic drugs has been approved as the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the survival benefit is still limited, especially in patients with high-risk features (Vp4, and/or bile duct invasion and/or tumor occupancy of ≥50% of the liver). Hepatic arterial infusion chemotherapy (HAIC) plus apatinib (an antiangiogenic drug) and camrelizumab (a PD-1 antibody) showed encouraging antitumor activity for these patients in a previous phase 2 study. Herein, we investigated the efficacy and safety of apatinib and camrelizumab plus HAIC compared with apatinib and camrelizumab as the first-line treatment for HCC with portal vein tumor thrombus (PVTT).

Abstract: TPS4194 | Poster Bd #: 167a

Abstracts & Presentations

Most patients with hepatocellular carcinoma (HCC) present with advanced unresectable or metastatic disease and survival rates remain poor. While approved checkpoint inhibitor (CPI)-based combination regimens for HCC have shown improvements in overall survival (OS), not all patients respond to currently available CPI-based therapy, and new strategies to overcome CPI-resistance using novel combination therapies are urgently needed. HCC gene expression profile analysis points to TGF-β signaling as a possible mechanism of immune escape. The first-in-class humanized monoclonal antibody livmoniplimab (ABBV-151) was developed that specifically binds to the glycoprotein-A repetitions predominant-transforming growth factor (GARP–TGF)-β complex, blocking release of active TGF-β1 and promoting immunoreactivity. A phase 1 study in HCC showed an overall response rate (ORR) of 42% (5/12) when combining livmoniplimab with the programmed cell death 1 inhibitor budigalimab (ABBV-181). We describe herein a phase 2/3 study of livmoniplimab + budigalimab in patients with locally advanced or metastatic HCC.

Abstract: TPS4190 | Poster Bd #: 165a

Abstracts & Presentations

Pancreatic cancer is the third most common cause of cancer death. Surgery offers the best survival rates however only a minority of patients are eligible. Approximately 15-20% of patients are deemed unresectable due to vascular involvement LA. Conversion of unresectable tumors, due to vascular involvement to resectable, is an unmet clinical need.

Abstract: TPS4204 | Poster Bd #: 172a

Abstracts & Presentations

Immune checkpoint inhibitors (ICI) are an integral part of the treatment for advanced or metastatic non-small cell lung cancer (NSCLC). Chest CT and pathology data is gathered in routine clinical practice, and each modality provides complementary information. Tumor microenvironment is spatially heterogeneous and temporally dynamic. CT images provide macro-level characteristics of multiple tumors, and tissue-based histopathologic biomarkers analyze a single representative tumor microenvironment in-depth. We developed a deep learning-based chest CT prediction model to predict response to ICIs and validated its performance independently and in combination with histopathologic biomarkers.

Abstract: 8536 | Poster Bd #: 400